Literature DB >> 2841541

The correlation between the direct and indirect detection of bovine leukemia virus infection in cattle.

G L Cockerell1, J Rovnak.   

Abstract

Ninety-three cattle from a herd naturally infected with bovine leukemia virus (BLV) were tested for the presence of BLV infection by two indirect indicators, anti-BLV antibodies and lymphocytosis, and two direct indicators, BLV provirus and BLV gp51 antigen expression in peripheral blood mononuclear cells (PBMC). Forty-eight percent (45/93) of the cattle were seropositive, and of these, 53% (24/45) were provirus-positive. Freshly isolated PBMC were negative for gp51 antigen expression, but 11 cattle were positive following short-term culture of their PBMC; 10 of these were seropositive/provirus-positive cattle, and one was a seropositive/provirus-negative cow. Lymphocytosis was present in eight cattle, all of which were seropositive/provirus-positive/gp51-positive. Four cattle were provirus-positive, but negative for all other indicators of BLV infection; a second blood sample was collected from three of these cattle at a later date, at which time two of the three had seroconverted. These results suggest that depending on the stage of the infection, the pathogenesis of BLV in cattle may involve fundamental differences in the host-viral relationship, including the number of cells infected or the number of copies of integrated provirus per cell, regulation of expression of viral antigens, induction of the anti-viral immune response, and the polyclonal or monoclonal proliferation of lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841541     DOI: 10.1016/0145-2126(88)90112-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  Assessment of bovine leukemia virus transcripts in vivo.

Authors:  J Rovnak; J W Casey
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Proviral detection and serology in bovine leukemia virus-exposed normal cattle and cattle with lymphoma.

Authors:  R M Jacobs; Z Song; H Poon; J L Heeney; J A Taylor; B Jefferson; W Vernau; V E Valli
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

3.  Detection of a novel bovine lymphotropic herpesvirus.

Authors:  J Rovnak; S L Quackenbush; R A Reyes; J D Baines; C R Parrish; J W Casey
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins.

Authors:  O Orlik; G A Splitter
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Pathogenicity of molecularly cloned bovine leukemia virus.

Authors:  J Rovnak; A L Boyd; J W Casey; M A Gonda; W A Jensen; G L Cockerell
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression.

Authors:  G H Cantor; T F McElwain; T A Birkebak; G H Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

7.  Involvement of the cyclic AMP-responsive element binding protein in bovine leukemia virus expression in vivo.

Authors:  E Adam; P Kerkhofs; M Mammerickx; R Kettmann; A Burny; L Droogmans; L Willems
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  In vivo transcription of the bovine leukemia virus tax/rex region in normal and neoplastic lymphocytes of cattle and sheep.

Authors:  W A Jensen; J Rovnak; G L Cockerell
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

9.  Identification of an NF-kappa B binding site in the bovine leukemia virus promoter.

Authors:  P A Brooks; J K Nyborg; G L Cockerell
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Inhibition of protein kinase C results in decreased expression of bovine leukemia virus.

Authors:  W A Jensen; B J Wicks-Beard; G L Cockerell
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.